Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



HPA-axis function and grey matter volume reductions: Imaging the diathesis-stress model in individuals at ultra-high risk of psychosis
Indexado
WoS WOS:000377305600003
Scopus SCOPUS_ID:84966441068
DOI 10.1038/TP.2016.68
Año 2016
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



The onset of psychosis is thought to involve interactions between environmental stressors and the brain, with cortisol as a putative mediator. We examined the relationship between the cortisol stress response and brain structure in subjects at ultra-high risk (UHR) for psychosis. Waking salivary cortisol was measured in 22 individuals at UHR for psychosis and 17 healthy controls. Grey matter volume was assessed using magnetic resonance imaging at 3 T. The relationship between the stress response and grey matter volume was investigated using voxel-based analyses. Our predictions of the topography of cortisol action as a structural brain modulator were informed by measures of brain glucocorticoid and mineralcorticoid receptor distribution obtained from the multimodal neuroanatomical and genetic Allen Brain Atlas. Across all subjects, reduced responsivity of the hypothalamus-pituitary-adrenal (HPA) axis was correlated with smaller grey matter volumes in the frontal, parietal and temporal cortex and in the hippocampus. This relationship was particularly marked in the UHR subjects in the right prefrontal, left parahippocampal/fusiform and parietal cortices. The subgroup that subsequently developed psychosis showed a significant blunting of HPA stress response, observed at trend level also in the whole UHR sample. Altered responses to stress in people at high risk of psychosis are related to reductions in grey matter volume in areas implicated in the vulnerability to psychotic disorders. These areas may represent the neural components of a stress vulnerability model.

Revista



Revista ISSN
Translational Psychiatry 2158-3188

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Psychiatry
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Valli, I. - Kings Coll London - Reino Unido
King's College London - Reino Unido
2 Crossley, Nicolas Hombre Kings Coll London - Reino Unido
Pontificia Universidad Católica de Chile - Chile
King's College London - Reino Unido
3 Day, F. - Kings Coll London - Reino Unido
King's College London - Reino Unido
4 Stone, J. - Kings Coll London - Reino Unido
King's College London - Reino Unido
5 Tognin, S. - Kings Coll London - Reino Unido
King's College London - Reino Unido
6 Mondelli, V. - Kings Coll London - Reino Unido
King's College London - Reino Unido
National Health Service - Reino Unido
South London and Maudsley NHS Foundation Trust - Reino Unido
7 Howes, O. - Kings Coll London - Reino Unido
Univ London Imperial Coll Sci Technol & Med - Reino Unido
King's College London - Reino Unido
Imperial College London - Reino Unido
8 Valmaggia, L. - Kings Coll London - Reino Unido
King's College London - Reino Unido
9 Pariante, C. - Kings Coll London - Reino Unido
King's College London - Reino Unido
National Health Service - Reino Unido
South London and Maudsley NHS Foundation Trust - Reino Unido
10 McGuire, P. Hombre Kings Coll London - Reino Unido
King's College London - Reino Unido

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Medical Research Council
NIHR
Servier
Lundbeck
Sunovion
Pfizer
AstraZeneca
National Institute for Health Research
Eli Lilly and Company
Eli Lilly
BMS
Roche
Janssen Pharmaceuticals
Astra-Zeneca
Roche Products
Academy of Medical Sciences (AMS)
Otsuka
Heptares
Jansenn
Rand
Lyden-Delta
Autifony
Sunovion and Hoffman-La Roche
Pfizer UK

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
JS has received honoraria from Janssen Pharmaceuticals, Behrenberg Bank, AstraZeneca, Pfizer, Sunovion and Hoffman-La Roche. OH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. IV was supported by NIHR clinical lectureship. The remaining authors declare no conflict of interest.
JS has received honoraria from Janssen Pharmaceuticals, Behrenberg Bank, AstraZeneca, Pfizer, Sunovion and Hoffman-La Roche. OH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. IV was supported by NIHR clinical lectureship. The remaining authors declare no conflict of interest.

Muestra la fuente de financiamiento declarada en la publicación.